Header Logo

Connection

Stuart Levitz to Glucans

This is a "connection" page, showing publications Stuart Levitz has written about Glucans.
Connection Strength

2.605
  1. Deepe GS, Buesing WR, Ostroff GR, Abraham A, Specht CA, Huang H, Levitz SM. Vaccination with an alkaline extract of Histoplasma capsulatum packaged in glucan particles confers protective immunity in mice. Vaccine. 2018 05 31; 36(23):3359-3367.
    View in: PubMed
    Score: 0.553
  2. Specht CA, Lee CK, Huang H, Tipper DJ, Shen ZT, Lodge JK, Leszyk J, Ostroff GR, Levitz SM. Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts. mBio. 2015 Dec 22; 6(6):e01905-15.
    View in: PubMed
    Score: 0.469
  3. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. Characterization and optimization of the glucan particle-based vaccine platform. Clin Vaccine Immunol. 2013 Oct; 20(10):1585-91.
    View in: PubMed
    Score: 0.399
  4. Soto ER, Specht CA, Rus F, Lee CK, Abraham A, Levitz SM, Ostroff GR. An efficient (nano) silica - In glucan particles protein encapsulation approach for improved thermal stability. J Control Release. 2023 05; 357:175-184.
    View in: PubMed
    Score: 0.194
  5. Hester MM, Oliveira LVN, Wang R, Mou Z, Lourenco D, Ostroff GR, Specht CA, Levitz SM. Cross-reactivity between vaccine antigens from the chitin deacetylase protein family improves survival in a mouse model of cryptococcosis. Front Immunol. 2022; 13:1015586.
    View in: PubMed
    Score: 0.188
  6. Specht CA, Homan EJ, Lee CK, Mou Z, Gomez CL, Hester MM, Abraham A, Rus F, Ostroff GR, Levitz SM. Protection of Mice against Experimental Cryptococcosis by Synthesized Peptides Delivered in Glucan Particles. mBio. 2021 02 22; 13(1):e0336721.
    View in: PubMed
    Score: 0.168
  7. Hester MM, Lee CK, Abraham A, Khoshkenar P, Ostroff GR, Levitz SM, Specht CA. Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. Vaccine. 2020 01 16; 38(3):620-626.
    View in: PubMed
    Score: 0.153
  8. Abraham A, Ostroff G, Levitz SM, Oyston PCF. A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogens. Clin Exp Immunol. 2019 11; 198(2):143-152.
    View in: PubMed
    Score: 0.152
  9. Whelan AO, Flick-Smith HC, Homan J, Shen ZT, Carpenter Z, Khoshkenar P, Abraham A, Walker NJ, Levitz SM, Ostroff GR, Oyston PCF. Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles. PLoS One. 2018; 13(10):e0200213.
    View in: PubMed
    Score: 0.142
  10. Specht CA, Lee CK, Huang H, Hester MM, Liu J, Luckie BA, Torres Santana MA, Mirza Z, Khoshkenar P, Abraham A, Shen ZT, Lodge JK, Akalin A, Homan J, Ostroff GR, Levitz SM. Vaccination with Recombinant Cryptococcus Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. mBio. 2017 11 28; 8(6).
    View in: PubMed
    Score: 0.134
  11. Whelan AO, Flick-Smith HC, Walker NJ, Abraham A, Levitz SM, Ostroff GR, Oyston PCF. A glucan-particle based tularemia subunit vaccine induces T-cell immunity and affords partial protection in an inhalation rat infection model. PLoS One. 2024; 19(5):e0294998.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.